Business Wire

Fluidigm Launches Low-Cost Assays for Gene Expression, SNP Genotyping and Target-Specific Primers for Next-Generation Sequencing

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm Corporation (NASDAQ:FLDM) today announced the availability of assays and primers optimized for the company’s integrated fluidic circuit ...
FiercePharma

Roche and Fluidigm Corporation Enter Worldwide Co-Promotion Agreement for 454 Sequencing Systems and Access Array™ Platfor

BRANFORD, Conn. & SAN FRANCISCO--(BUSINESS WIRE)-- 454 Life Sciences, a Roche Company, and Fluidigm Corporation announced today that they have entered a worldwide co-promotional agreement for the ...